Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach

Table 9 Plasma miRNA results in MD patients with normal vs. impaired systolic function

miRNA plasma levels^a (/10³)	Normal LV and RV function	Impaired LV and/or RV function	p value
miRNA plasma levels^a (/10³)	N = 31	N = 32	p value
-206	31.77 (4.83–79.62)	11.27(3.52–50.27)	0.58
-144-5p	33.14 (0.00–525.08)	0.00 (0.00–98.72)	0.29
-146b	74.79 (0.00–173.85)	29.92 (0.00–177.79)	0.60
-15b	0.00 (0.00–18.15)	0.18 (0.00–21.81)	0.77
-195	9.01 (0.35–18.62)	8.93 (1.90–22.0)	0.66
-20b	53.99 (25.84–83.60)	65.45 (19.35–87.12)	0.66
-21	42.09 (0.00–102.71)	13.65 (0.00–150.01)	0.41
-221	0.00 (0.00–18.27)	0.00 (0.00–18.55)	0.36
-222	1801.09 (1215.81–3491.60)	2006.29 (638.43–6059.36)	0.79
-26a	283.14 (110.62–512.14)	362.31 (121.25–622.72)	0.36
-29a	0.00 (0.00–0.00)	0.00 (0.00–0.05)	0.39
-29c	0.00 (0.00–0.47)	0.00 (0.00–2.16)	0.27
-342	2249.28 (1294.10–3353.27)	2570.15 (888.62–5565.11)	0.54
-378a-3p	28.84 (6.04–155.98)	32.92 (1.76–301.61)	0.98
-378a-5p	27.57 (12.50–56.49)	26.02 (7.00–84.56)	0.78
−451	184.13 (100.07–349.44)	171.93 (22.68–307.38)	0.77
−93	26.19 (0.00–70.81)	27.17 (0.00–53.75)	0.81

(^a) – Each miRNA plasma level was normalized to miR-16 plasma levels and thereafter multiplied by 10³ in order to increase readability
Bold text indicates a significant p-value of <0.05

ISSN: 1532-429X